"We are excited to welcome Susanne and Serge to our team, especially as we scale up our clinical and commercial activities during our transition to becoming a biopharmaceutical company," said Daniel Cohen, M.D., Ph.D., Pharnext's Co-Founder and Chief Executive Officer.

"Susanne's deep regulatory expertise and Serge's extensive experience in clinical development will be great assets to our team. We look forward to Susanne and Serge's insights as we continue to progress our late-stage pipeline and prepare the regulatory package in order to commercialize PXT3003 for Charcot-Marie-Tooth Disease type 1A (CMT1A)."
Before joining Pharnext, Susanne worked as Head of Regulatory Affairs for Immunology and Neurology at Sanofi Genzyme in Boston, MA. Prior to that, she held Regulatory Affairs leadership roles at Sanofi, Halozyme Therapeutics, Amylin Pharmaceuticals, Pfizer and Ciba/Novartis in the U.S. and Europe, supporting multiple therapeutic areas.
Serge joins Pharnext from Gensight Biologics, where he served as Director of Medical Affairs. Previously, he worked as Global Therapeutic Area Head at Novartis and as Clinical Research Director in Clinical Pharmacology at Sanofi. Before that, Serge served as Chief Medical Officer at Tilak Healthcare and was also Founder and CEO of Mediscis, a CRO specialised in early-stage clinical trials. He has broad experience leading early- to late-stage clinical development and more than 25 years of experience in pharmaceutical, medical device and gene therapy product development.